Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
AssigneeTwinstrand Therapeutics Inc.
InventorsThor Borgford, Curtis Braun, Admir Purac, Dominik Stoll
Life of this patent
Estimating the term…
Loading patent…
AssigneeTwinstrand Therapeutics Inc.
InventorsThor Borgford, Curtis Braun, Admir Purac, Dominik Stoll
Estimating the term…
The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a disease specific protease such as a cancer, inflammatory, fungal, viral or parasitic protease. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. In addition, the invention relates to a method for producing the recombinant protein in yeast, to nucleic acid molecules for use in yeast and to yeast transformed with such nucleic acid molecules. Also provided is a method of inhibiting or destroying mammalian cancer cells, inflammatory cells, cells infected with a virus, a fugus, or parasite, or parasites utilizing the nucleic acid molecules and proteins of the invention and pharmaceutical compositions for treating human cancer, inflammatory disease, viral infection, fugal infection, or parasitic infection.
A purified and isolated nucleic acid sequence having a nucleotide sequence encoding an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence linking the A and B chains, the heterologous linker sequence containing a cleavage recognition site for a protease selected from the group consisting of:
Dependencies are inferred from the claim text.